Showing 1 - 6 results of 6 for search 'Susan Ju', query time: 0.03s Refine Results
  1. 1
    Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies

    Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies by Terry A. Jacot, Meredith R. Clark, Oluwatosin E. Adedipe, Susan Godbout, Abby G. Peele, Susan Ju, Jill L. Schwartz, Andrea R. Thurman, Gustavo F. Doncel

    Published 2018-11-01
    Get full text
    Article
  2. 2
    Application of a composite measure of product adherence, protocol compliance, and semen exposure to a phase III microbicide HIV prevention trial

    Application of a composite measure of product adherence, protocol compliance, and semen exposure to a phase III microbicide HIV prevention trial by Terry A. Jacot, Meredith R. Clark, Oluwatosin E. Adedipe, Susan Godbout, Tina Cunningham, Susan Ju, Jill L. Schwartz, Sinead Delany-Moretlwe, Andrea R. Thurman, Gustavo F. Doncel

    Published 2021-09-01
    Get full text
    Article
  3. 3
    The use of objective adherence measures targeting four placebo microbicide delivery forms in the Quatro Clinical Crossover Study

    The use of objective adherence measures targeting four placebo microbicide delivery forms in the Quatro Clinical Crossover Study by Terry A. Jacot, Oluwatosin E. Adedipe, Susan Godbout, Abby G. Peele, Jill L. Schwartz, Susan Ju, Tina D. Cunningham, Elizabeth Montgomery, Ariane van derStraten, Mags Beksinska, Jenni Smit, Nyaradzo Mgodi, Andrea R. Thurman, Meredith R. Clark, Gustavo F. Doncel

    Published 2021-10-01
    Get full text
    Article
  4. 4
    Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.

    Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continu... by Andrea R Thurman, Vivian Brache, Leila Cochon, Louise A Ouattara, Neelima Chandra, Terry Jacot, Nazita Yousefieh, Meredith R Clark, Melissa Peet, Homaira Hanif, Jill L Schwartz, Susan Ju, Mark A Marzinke, David W Erikson, Urvi Parikh, Betsy C Herold, Raina N Fichorova, Elizabeth Tolley, Gustavo F Doncel

    Published 2022-01-01
    Get full text
    Article
  5. 5
    Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial

    Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled... by Andrea R. Thurman, MD, Jill L. Schwartz, MD, Mackenzie L. Cottrell, PharmD, Vivian Brache, Lic, Beatrice A. Chen, MD, MPH, Leila Cochón, Lic, Susan Ju, BA, Ian McGowan, MD PhD, James F. Rooney, MD, Scott McCallister, MD, Gustavo F. Doncel, MD PhD

    Published 2021-06-01
    Get full text
    Article
  6. 6
    Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study

    Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continu... by Andrea R. Thurman, Vivian Brache, Leila Cochon, Louise A. Ouattara, Neelima Chandra, Terry Jacot, Nazita Yousefieh, Meredith R. Clark, Melissa Peet, Homaira Hanif, Jill L. Schwartz, Susan Ju, Mark A. Marzinke, David W. Erikson, Urvi Parikh, Betsy C. Herold, Raina N. Fichorova, Elizabeth Tolley, Gustavo F. Doncel

    Published 2022-01-01
    Get full text
    Article

Search Tools: